Our Pricing

Understanding Mounjaro Tablet Form: UK Availability and Oral Alternatives

Published: 10 September 2026

Many patients searching for mounjaro tablet form are seeking an oral alternative to the weekly injection. Currently, Mounjaro (tirzepatide) is only licensed in the UK as a subcutaneous injection administered via KwikPen. However, oral GLP-1 receptor agonist tablets are now available, offering convenient pill-based weight loss treatment for those who prefer not to inject.

Is Mounjaro Tablet Form Currently Available in the UK?

Mounjaro tablet form is not currently licensed or available in the United Kingdom. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Mounjaro exclusively as a pre-filled injection pen containing tirzepatide solution [1]. This formulation is administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm.

While pharmaceutical manufacturer Eli Lilly has announced development of an oral tirzepatide formulation, this tablet version has not yet received regulatory approval in the UK or European Union [2]. Clinical trials for oral tirzepatide are ongoing, with early-phase studies showing promising results for weight reduction and glycaemic control. Until regulatory approval is granted, UK patients can only access tirzepatide through the licensed injection format.

For patients specifically seeking a tablet alternative to Mounjaro injections, Wegovy Oral Tablets (oral semaglutide) represent the only MHRA-licensed GLP-1 receptor agonist pill currently available for weight management in the UK. This once-daily tablet offers a needle-free option with clinically proven efficacy.

Why Mounjaro Tablet Form Is Not Yet Licensed: Formulation Challenges

The absence of mounjaro tablet form in the UK market reflects significant pharmaceutical challenges inherent to peptide-based medications like tirzepatide. GLP-1 receptor agonists are large protein molecules that are rapidly degraded by digestive enzymes in the stomach and intestines, making oral bioavailability extremely poor without specialised formulation technology [3].

Developing an effective oral version of tirzepatide requires advanced delivery systems to protect the active molecule during gastrointestinal transit and enhance absorption across the intestinal wall. This typically involves absorption enhancers, enteric coatings, or novel carrier technologies that can substantially increase manufacturing complexity and cost.

Novo Nordisk's success with oral semaglutide (Wegovy tablets) utilised a proprietary absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to facilitate uptake in the stomach [4]. Similar technologies would be required for any future mounjaro tablet form, necessitating extensive clinical trials to demonstrate comparable efficacy and safety to the injection.

Clinical Trial Progress for Oral Tirzepatide

Eli Lilly initiated Phase 1 clinical trials for an oral tirzepatide formulation in 2023, evaluating pharmacokinetics, safety, and tolerability in healthy volunteers. Early data presented at scientific conferences suggest that oral delivery of tirzepatide is feasible, though optimal dosing regimens and absorption enhancement strategies are still being refined [2]. These studies represent the first step in a multi-year regulatory pathway before any mounjaro tablet form could reach UK pharmacies.

Mounjaro Tablet Form Alternatives: Wegovy Oral Tablets Explained

For patients seeking a tablet alternative to mounjaro injection form, Wegovy Oral Tablets (oral semaglutide) provide an MHRA-licensed option available from £124.99 at Cured Pharmacy. This once-daily pill contains the same active ingredient as Wegovy injections—semaglutide, a GLP-1 receptor agonist—formulated for oral administration with proven weight loss efficacy [4].

In the OASIS 1 clinical trial, participants taking oral semaglutide 50mg daily achieved an average weight reduction of 15.1% over 68 weeks, compared to 2.4% with placebo [5]. While this represents slightly lower weight loss than injectable semaglutide or tirzepatide, the convenience of a daily tablet makes it an attractive choice for individuals with needle aversion or lifestyle preferences favouring oral medication.

Wegovy tablets must be taken on an empty stomach with a small amount of water (up to 120ml), at least 30 minutes before any food, drink, or other medications. This administration requirement differs from the weekly injection schedule of Mounjaro, but many patients find the daily routine easier to incorporate into their morning habits.

How Wegovy Tablets Compare to Mounjaro Injections

Both Wegovy oral tablets and Mounjaro injections are GLP-1-based therapies that reduce appetite, slow gastric emptying, and improve glycaemic control. However, tirzepatide (Mounjaro) also activates GIP receptors, potentially offering enhanced weight loss—clinical trials showed average reductions of 20.9% with Mounjaro 15mg versus 14.9% with injectable semaglutide 2.4mg [1]. The trade-off for patients considering a mounjaro tablet form alternative is accepting slightly lower efficacy in exchange for oral convenience and avoiding injections entirely.

Current Mounjaro Injection Form: Dosing and Administration

Until mounjaro tablet form becomes available, UK patients access tirzepatide exclusively through the KwikPen injection device. Treatment begins with a 2.5mg once-weekly dose for four weeks, serving as an initial tolerability phase to minimise gastrointestinal side effects. The dose is then increased to 5mg weekly, with further escalations to 7.5mg, 10mg, 12.5mg, and a maximum of 15mg based on individual response and tolerability [1].

Each Mounjaro pen is pre-filled with a single dose and designed for subcutaneous self-administration. Patients rotate injection sites between the abdomen, thigh, and upper arm to reduce lipohypertrophy risk. The injection process takes less than one minute, and most individuals report minimal discomfort with the fine-gauge needle.

At Cured Pharmacy, Mounjaro injections are available from £124.99 following a free online clinical assessment by UK-registered prescribers. Our transparent pricing model shows the exact cost before you complete your consultation, and first-time patients receive £20 off with code Weightlossnew, reducing the initial price to £124.99.

Will Mounjaro Tablet Form Be Available in the UK Soon?

While pharmaceutical development timelines are difficult to predict with certainty, industry observers anticipate that mounjaro tablet form could potentially reach the UK market within 3-5 years, subject to successful completion of Phase 2 and Phase 3 clinical trials and subsequent MHRA regulatory review [2]. Eli Lilly has publicly stated that oral tirzepatide is a strategic priority, given the commercial success of oral semaglutide and patient preference data showing strong demand for non-injectable weight loss medications.

Before any mounjaro tablet form receives UK licensure, it must demonstrate non-inferior efficacy to the injection in large-scale randomised controlled trials, typically involving thousands of participants followed for 12-18 months. Safety data must also confirm that the oral formulation does not introduce new adverse effects related to gastrointestinal absorption or systemic exposure patterns.

Patients interested in being among the first to access oral tirzepatide when approved should maintain regular contact with their prescribing clinician or pharmacy. Cured Pharmacy will update our weight loss treatment portfolio as soon as any mounjaro tablet form receives MHRA authorisation, ensuring UK patients benefit from the latest evidence-based options.

Regulatory Pathway for New Formulations

The MHRA follows a rigorous evaluation process for new pharmaceutical formulations, even when the active ingredient is already approved in another format. An oral tirzepatide submission would require comprehensive chemistry, manufacturing, and controls (CMC) data, plus clinical evidence demonstrating bioequivalence or therapeutic equivalence to the injection. This regulatory pathway typically spans 12-18 months from application submission to approval decision, assuming no major deficiencies requiring additional studies.

Choosing Between Mounjaro Injection and Oral Tablet Alternatives

For patients who specifically want mounjaro tablet form but cannot wait for future regulatory approval, the decision centres on whether to use the currently available Mounjaro injection or switch to an oral GLP-1 tablet like Wegovy. This choice depends on individual priorities: maximising weight loss efficacy versus avoiding injections entirely.

Clinical evidence suggests that Mounjaro injections deliver superior weight reduction compared to oral semaglutide—the SURPASS-2 trial demonstrated that tirzepatide 15mg achieved 12.4kg average weight loss versus 6.2kg with injectable semaglutide 1mg over 40 weeks [1]. However, the OASIS 1 trial showed oral semaglutide 50mg produced meaningful 15.1% body weight reduction, which many patients find sufficient to meet their health goals [5].

Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides personalised guidance during your free online consultation to help determine which formulation aligns best with your medical history, weight loss targets, and lifestyle preferences. Both options require ongoing prescriber oversight and are subject to clinical assessment for suitability.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 10 September 2026]
2. Eli Lilly and Company. (2023). Lilly provides update on oral GLP-1 receptor agonist development program. Corporate press release. [accessed 10 September 2026]
3. Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., ... & Knudsen, L. B. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. [accessed 10 September 2026]
4. Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., ... & PIONEER 10 investigators. (2020). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 398(10306), 705-719. [accessed 10 September 2026]
5. Wilding, J. P., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 10 September 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.